KALV (KalVista Pharmaceuticals) Short-Term Debt to Capital
KalVista Pharmaceuticals (KALV) management ensures full transparency of HAE treatment trials, backed by a high level of expertise in immunology. The development of this biotech is not tied to market cycles but relies on medical outcomes, although the macro environment impacts equity issuances. The asset value tracked on this chart, in the context of the debt-to-equity ratio, is 0.00. The stability of the R&D core is guaranteed by long-term employee stock options.
Analytical breakdowns for KalVista Pharmaceuticals
- stock quotes and analyst forecast:
- business market valuation indicators:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital KalVista Pharmaceuticals|KALV - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio KalVista Pharmaceuticals, Inc.|KALV - Aggregate Debt Obligations|Debts to Book Capitalization KalVista Pharma|KALV - Long-Term Debt Volume|Company Short-Term Debt KalVista Pharmaceuticals|Quick Liquidity kalvista.com
- company profitability and valuation multiples indicators:
Fundamental valuation:KalVista Pharmaceuticals Inc
The anticipation of commercializing drugs for angioedema requires KalVista Pharmaceuticals (KALV) to maintain strict liquidity management to sustain high market confidence. This ratio correlates liabilities with maturities of up to one year against equity, determining the company's degree of reliance on short-term borrowing when building reserves. By analyzing current debt under one year relative to equity, an investor assesses the financial maturity of the structure and the risk of losing stability during a sharp reduction in leverage.
Main competitors
Short-Term Debt to Capital ARGX|BNTX (BioNTech Pharma) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ABVX (Abivax Pharma)|Short-Term Debt to Capital admabiologics.com ADMA|PTGX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital IMVT (Immunovant Inc)|Kiniksa Pharmaceuticals Ltd (KNSA) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Grifols Biemat|ADPT (Adaptive Biotechnologies) - Short-Term Debt to Capital|Short-Term Debt to Capital celldex.com|Short-Term Debt to Equity Ratio AUPH (Aurinia Pharmaceuticals Inc.)|BCRX (BioCryst Pharmaceuticals, Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VERA (Vera Pharma)|Short-Term Debt to Capital Coefficient Dianthus Corp (DNTH)|PHVS - Short-Term Debt to Equity|AbCellera Biologics Inc (ABCL) - Short-Term Debt to Equity Ratio|Tourmaline Bio (TRML) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Precigen Inc|Short-Term Debt to Equity Ratio PHAR|Short-Term Debt to Capital Nektar Corp|Short-Term Debt to Equity Upstream Bio Inc (UPB)|zenasbio.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital IMNM (Immunome)|Gossamer Bio Inc (GOSS) - Current Liabilities to Capital|SEPN - Short-Term Debt to Equity|PVLA - Short-Term Debt to Capital|SVRA: Short-Term Debt to Capital|rigel.com (RIGL) - Short-Term Debt to Capital|Short-Term Debt to Equity AnaptysBio|Short-Term Debt to Equity ATXS|Short-Term Debt to Equity Ratio ENGN (enGene Bio)|Short-Term Debt to Equity RAPT (rapt.com)|Short-Term Debt to Capital JBIO (Aerovate Therapeutics)|Short-Term Debt to Capital Coefficient aclaristx.com (ACRS)|KYTX - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Tiziana Life Sciences Ltd. TLSA|CABA (Cabaletta Bio, Inc) - Short-Term Debt to Equity Ratio|VTYX: Short-Term Loans to Capital Ratio|THTX (Theratechnologies Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital avalotx.com|Short-Term Debt to Equity Ratio ELDN (Eledon Pharmaceuticals, Inc.)|AGEN (Agenus, Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Climb Bio, Inc. CLYM|ZURA (zurabio.com) - Current Liabilities to Equity|aTyr Pharma, Inc. - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital ADAG (Adagene)|IMA: Short-Term Debt to Capital|Shattuck Labs (STTK) - Short-Term Debt to Capital|Short-Term Debt to Equity Equillium Inc|CNTB: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Immunic, Inc. (IMUX)|Short-Term Debt to Equity Ratio atarabio.com ATRA|Short-Term Debt to Capital IFRX (InflaRx)|Short-Term Debt to Capital X4 Pharmaceuticals Inc. XFOR|Adicet - Short-Term Debt to Capital|Celularity Inc. (CELU) - Short-Term Debt to Equity Ratio|INMB: Short-Term Debt to Capital|Current Liabilities to Capital barinthusbio.com (BRNS)|Short-Term Debt to Equity Ratio KZR|Short-Term Debt to Capital SAB Biotherapeutics Inc.|Short-Term Debt to Equity Ratio AKTX (Akari Therapeutics plc)|Short-Term Loans to Capital Ratio ENLV|Short-Term Debt to Capital QTTB (Q32 Bio)|Short-Term Debt to Capital Coefficient geovax.com (GOVX)|Edesa Biotech - Short-Term Debt to Capital|iBio Inc (IBIO) - Short-Term Debt to Equity Ratio|CARM: Short-Term Debt to Capital|XTL Bio (XTLB) - Short-Term Debt to Capital|Short-Term Debt to Equity Bolt Biotherapeutics Inc.|Short-Term Debt to Equity HCWB|Short-Term Debt to Equity Aptevo Therapeutics (APVO)|Short-Term Debt to Capital Coefficient aimimmuno.com|Short-Term Debt to Equity Aditxt, Inc. ADTX|Short-Term Debt to Capital GRI Bio Corporation GRI|XORTX Therapeutics Inc. - Short-Term Debt to Capital|HIND - Short-Term Debt to Capital|Revelation Biosciences, Inc. (REVB) - Short-Term Debt to Equity|INDP (Indaptus Therapeutics Inc) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio SCNI|Short-Term Debt to Equity CALI|Short-Term Debt to Equity Affimed (AFMD)|ALLK: Current Liabilities to Equity|Short-Term Debt to Capital HOOK (HOOKIPA Pharma)|Ratio of Short-Term Indebtedness to Capital IGMS|iTeos - Short-Term Debt to Capital|OCEA - Short-Term Debt to Capital|TC Biopharm (TCBP) - Short-Term Debt to Equity|thirdharmonicbio.com - Ratio of Short-Term Indebtedness to Capital